March 1, 1990Journal of Clinical MicrobiologyOpen Access

Clinical studies of a quadrivalent rotavirus vaccine in Venezuelan infants

View Full Paper

Ask AI

Bookmark

Why the study?

Does an oral quadrivalent rotavirus vaccine demonstrate safety and antigenicity in infants?

Structured PICO

Does an oral quadrivalent rotavirus vaccine demonstrate safety and antigenicity in infants?

Population

130 Venezuelan infants 10 to 20 weeks of age

Intervention

Oral quadrivalent rotavirus vaccine (mixture of equal amounts of rhesus rotavirus (RRV) vaccine and three human rotavirus-RRV reassortant strains) at three different doses (0.25 x 10^4, 0.5 x 10^4, and 10^4 PFU of each component)

Comparator

Placebo

Outcome

Safety and antigenicity (serum immunoglobulin A response, neutralizing antibodies, and vaccine virus shedding)safety

The oral quadrivalent rotavirus vaccine was safe and immunogenic in Venezuelan infants, eliciting a serum IgA response in the majority of recipients.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Supports further development of quadrivalent rotavirus vaccines; extends immunogenicity data to Venezuelan infants.

Cite This Study

Pérez‐Schael et al. (1990) studied this question.

synapsesocial.com/papers/6a786102576efb0ddaf80d61 https://doi.org/10.1128/jcm.28.3.553-558.1990

View Full Paper

Ask AI

Bookmark

Clinical studies of a quadrivalent rotavirus vaccine in Venezuelan infants

Structured PICO

Discussion

Implication

Cite This Study

Clinical studies of a quadrivalent rotavirus vaccine in Venezuelan infants

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider